Jonathan A Pachter

6PUBLICATIONS
79CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 23, 2024
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy.

Xiuting Liu, John M Baer, Meredith L Stone

|Jun 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.

Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos

|Apr 18, 2023
Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.

Shih-Shih Chen, Jacqueline C Barrientos, Gerardo Ferrer

|Jan 27, 2022
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.

Christopher Ronald Funk, Shuhua Wang, Kevin Z Chen

|Feb 11, 2021
Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma.

Justine S Paradis, Monica Acosta, Robert Saddawi-Konefka

|May 15, 2020
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.

Xiangmeng Wang, Po Yee Mak, Hong Mu

Pageof 1

Frequent Collaborators

1 joint publications

Michael Andreeff

1 joint publications

Monica Acosta

1 joint publications

Robert Saddawi-Konefka

1 joint publications

Frederico Gomes